KymaThera

Pipeline Programs Discovery IND Enabling Phase 1/2a Phase 2 PI3Kα Pan-mut K-1728 + K-1728 is an investigational, oral, pan-mutant selective PI3Kα inhibitor designed to potently inhibit disease-driving kinase and helical domain mutations while sparing wild-type PI3Kα. KymaThera designed K-1728 using its structure-based drug discovery capabilities to address key limitations of earlier generations of PI3Kα inhibitors, […]

News KymaThera Announces $80 Million Series B Financing to Advance K-1728, a Next-Generation Pan-Mutant Selective PI3Kα Inhibitor, for Cancer and Vascular Malformations KymaThera announced the closing of an $80 million Series B financing to advance K-1728, its investigational, oral, pan-mutant selective PI3Kα inhibitor, into clinical development. The company expects to initiate patient dosing in a […]

Mr. Geremia brings over a decade of finance and executive leadership experience in the biotech industry, spanning early discovery through clinical development. He has held senior leadership positions in venture backed biotechs across multiple therapeutic areas where he has led financing activities, financial planning, corporate strategy, and operations, guiding preclinical and early clinical programs toward […]

To learn more about KymaThera’s programs or partnership opportunities, please reach out.

KymaThera applies deep scientific insights and disciplined execution to deliver best-in-class medicines.

Last revised: December 2025 This Cookie Policy explains how KymaThera (“Company”, “we”, or “our”) uses cookies and similar technologies when you visit www.kymathera.com (the “Website”). It should be read together with our www.kymathera.com/privacy-policy/. What Are Cookies Cookies are small text files placed on your computer or device when you visit a website. They are widely used […]

Last revised: December 2025   KymaThera (“Company”, “we”, or “our”) respects your privacy. This Privacy Policy describes the types of information we may collect from you or that you may provide when you visit www.kymathera.com (our “Website”) and our practices for collecting, using, maintaining, protecting, and disclosing that information. It also describes your rights under […]

Last revised: December 2025 These Terms of Use (“Terms”) govern your access to and use of KymaThera’s website (the “Site”). By accessing or using the Site, you agree to be bound by these Terms and by our www.kymathera.com/privacy-policy/. If you do not agree, you may not use the Site. Use of the Site The content […]

San Diego-based biotech KymaThera raises $80m in a Series B funding round to bring a breast cancer drug to clinic. The candidate is intended to address limitations of existing PI3Kα therapies, while the funding supports its move into clinical development.

Oct 2026 · Pharmaceutical TechnologyNews article

KymaThera raises $80 million in a Series B round to support a Phase I trial of its PI3Kα inhibitor. Some of the financing will fund the trial, which the headline describes as a breast cancer study.

Oct 2026 · GenomeWebNews article

KymaThera closes an $80 million Series B financing to advance its lead investigational candidate, K-1728, toward clinical development. K-1728 is a PI3Kα inhibitor.

Oct 2026 · PharmacallyNews article

KymaThera raises $80 million in Series B financing to advance development of K-1728, its investigational cancer drug. K-1728 is an oral PI3Kα inhibitor.

Oct 2026 · Pharma JournalistNews article